"It Gives Them More Options": Preferences for Preconception Genetic Carrier Screening for Fragile X Syndrome in Primary Healthcare

Overview

Journal J Community Genet

Publisher Springer

Specialty Health Services

Date 2016 Feb 5

PMID 26842720

Citations 13

Authors

Alison D Archibald

Chriselle L Hickerton

Samantha A Wake

Alice M Jaques

Jonathan Cohen

Sylvia A Metcalfe

Affiliations

Soon will be listed here.

Abstract

This study aims to explore stakeholder views about offering population-based genetic carrier screening for fragile X syndrome. A qualitative study using interviews and focus groups with stakeholders was undertaken to allow for an in-depth exploration of views and perceptions about practicalities of, and strategies for, offering carrier screening for fragile X syndrome to the general population in healthcare settings. A total of 188 stakeholders took part including healthcare providers (n = 81), relatives of people with fragile X syndrome (n = 29), and members of the general community (n = 78). The importance of raising community awareness about screening and providing appropriate support for carriers was emphasized. There was a preference for preconception carrier screening and for providing people with the opportunity to make an informed decision about screening. Primary care was highlighted as a setting which would ensure screening is accessible; however, challenges of offering screening in primary care were identified including time to discuss screening, knowledge about the test and possible outcomes, and the health professionals' approach to offering screening. With the increasing availability of genetic carrier tests, it is essential that research now focuses on evaluating approaches for the delivery of carrier screening programs. Primary healthcare is perceived as an appropriate setting through which to access the target population, and raising awareness is essential to making genetic screening more accessible to the general community.

Citing Articles

Population-based FMR1 carrier screening among reproductive women.

Ain Q, Hwang Y, Yeung D, Panpaprai P, Iamurairat W, Chutimongkonkul W J Assist Reprod Genet. 2024; 41(11):3237-3243.

PMID: 39320553 PMC: 11621265. DOI: 10.1007/s10815-024-03242-2.

Insight and Recommendations for Fragile X-Premutation-Associated Conditions from the Fifth International Conference on Premutation.

Tassone F, Protic D, Allen E, Archibald A, Baud A, Brown T Cells. 2023; 12(18).

PMID: 37759552 PMC: 10529056. DOI: 10.3390/cells12182330.

Multilevel barriers and facilitators to widespread use of preconception carrier screening in the United States.

Hull L, Flannery K, Kaimal A, Sepucha K, Rehm H, Haas J Genet Med. 2023; 25(12):100946.

PMID: 37534745 PMC: 10825062. DOI: 10.1016/j.gim.2023.100946.

The Australian Reproductive Genetic Carrier Screening Project (Mackenzie's Mission): Design and Implementation.

Archibald A, McClaren B, Caruana J, Tutty E, King E, Halliday J J Pers Med. 2022; 12(11).

PMID: 36579509 PMC: 9698511. DOI: 10.3390/jpm12111781.

The diagnostic experience of women with fragile X-associated primary ovarian insufficiency (FXPOI).

Poteet B, Ali N, Bellcross C, Sherman S, Espinel W, Hipp H J Assist Reprod Genet. 2022; 40(1):179-190.

PMID: 36447079 PMC: 9840735. DOI: 10.1007/s10815-022-02671-1.

References

Tambor E, Bernhardt B, Chase G, Faden R, Geller G, Hofman K . Offering cystic fibrosis carrier screening to an HMO population: factors associated with utilization. Am J Hum Genet. 1994; 55(4):626-37. PMC: 1918300. View

Henneman L, Bramsen I, VAN DER Ploeg H, Ader H, van der Horst H, Gille J . Participation in preconceptional carrier couple screening: characteristics, attitudes, and knowledge of both partners. J Med Genet. 2001; 38(10):695-703. PMC: 1734747. DOI: 10.1136/jmg.38.10.695. View

Tassone F, Pan R, Amiri K, Taylor A, Hagerman P . A rapid polymerase chain reaction-based screening method for identification of all expanded alleles of the fragile X (FMR1) gene in newborn and high-risk populations. J Mol Diagn. 2008; 10(1):43-9. PMC: 2175542. DOI: 10.2353/jmoldx.2008.070073. View

Hagerman P . The fragile X prevalence paradox. J Med Genet. 2008; 45(8):498-9. PMC: 2728763. DOI: 10.1136/jmg.2008.059055. View

Henneman L, Bramsen I, VAN DER Ploeg H, Ten Kate L . Preconception cystic fibrosis carrier couple screening: impact, understanding, and satisfaction. Genet Test. 2002; 6(3):195-202. DOI: 10.1089/109065702761403351. View

Poppelaars F, Henneman L, Ader H, Cornel M, Hermens R, van der Wal G . How should preconceptional cystic fibrosis carrier screening be provided? Opinions of potential providers and the target population. Community Genet. 2004; 6(3):157-65. DOI: 10.1159/000078163. View

Hagerman R, Leehey M, Heinrichs W, Tassone F, Wilson R, Hills J . Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology. 2001; 57(1):127-30. DOI: 10.1212/wnl.57.1.127. View

Ryynanen M, Heinonen S, Makkonen M, Kajanoja E, Mannermaa A, Pertti K . Feasibility and acceptance of screening for fragile X mutations in low-risk pregnancies. Eur J Hum Genet. 1999; 7(2):212-6. DOI: 10.1038/sj.ejhg.5200285. View

Archibald A, Hickerton C, Jaques A, Wake S, Cohen J, Metcalfe S . "It's about having the choice": stakeholder perceptions of population-based genetic carrier screening for fragile X syndrome. Am J Med Genet A. 2012; 161A(1):48-58. DOI: 10.1002/ajmg.a.35674. View

10.

Acharya K, Friedman Ross L . Fragile X screening: attitudes of genetic health professionals. Am J Med Genet A. 2009; 149A(4):626-32. PMC: 3632082. DOI: 10.1002/ajmg.a.32725. View

11.

Metcalfe S . Carrier screening in preconception consultation in primary care. J Community Genet. 2011; 3(3):193-203. PMC: 3419291. DOI: 10.1007/s12687-011-0071-z. View

12.

Sherman S, Pletcher B, Driscoll D . Fragile X syndrome: diagnostic and carrier testing. Genet Med. 2005; 7(8):584-7. PMC: 3110946. DOI: 10.1097/01.gim.0000182468.22666.dd. View

13.

van Schendel R, Kleinveld J, Dondorp W, Pajkrt E, Timmermans D, Holtkamp K . Attitudes of pregnant women and male partners towards non-invasive prenatal testing and widening the scope of prenatal screening. Eur J Hum Genet. 2014; 22(12):1345-50. PMC: 4231403. DOI: 10.1038/ejhg.2014.32. View

14.

Metcalfe S, Archibald A, Couns G . Fragile X population carrier screening. Genet Med. 2012; 14(3):350. DOI: 10.1038/gim.2011.79. View

15.

Grody W, Thompson B, Gregg A, Bean L, Monaghan K, Schneider A . ACMG position statement on prenatal/preconception expanded carrier screening. Genet Med. 2013; 15(6):482-3. DOI: 10.1038/gim.2013.47. View

16.

Metcalfe S, Jacques A, Archibald A, Burgess T, Collins V, Henry A . A model for offering carrier screening for fragile X syndrome to nonpregnant women: results from a pilot study. Genet Med. 2008; 10(7):525-35. DOI: 10.1097/gim.0b013e31817c036e. View

17.

Anido A, Carlson L, Sherman S . Attitudes toward fragile X mutation carrier testing from women identified in a general population survey. J Genet Couns. 2007; 16(1):97-104. DOI: 10.1007/s10897-006-9049-0. View

18.

McWalter K, Sdano M, Dave G, Powell K, Callanan N . Public health genetic counselors: activities, skills, and sources of learning. J Genet Couns. 2014; 24(3):438-51. DOI: 10.1007/s10897-014-9795-3. View

19.

de Jong A, De Wert G . Prenatal screening: an ethical agenda for the near future. Bioethics. 2014; 29(1):46-55. DOI: 10.1111/bioe.12122. View

20.

Temel S, van Voorst S, de Jong-Potjer L, Waelput A, Cornel M, de Weerd S . The Dutch national summit on preconception care: a summary of definitions, evidence and recommendations. J Community Genet. 2014; 6(1):107-15. PMC: 4286565. DOI: 10.1007/s12687-014-0204-2. View